DOP54 Efficacy and safety of ustekinumab through Week 16 in patients with moderate-to-severe ulcerative colitis randomised to ustekinumab: results from the UNIFI induction trial

Authors :: J Izanec
S. R. Targan
David Rowbotham
Sheldon Sloan
Jewel Johanns
Christopher D. O'Brien
Philippe Szapary
Bruce E. Sands
Hongyan Zhang
Silvio Danese
Colleen Marano
Rupert W. Leong
G. Van Assche
Source :: Journal of Crohn's and Colitis. 13:S061-S062
Publication Year :: 2019
Publisher :: Oxford University Press (OUP), 2019.

Subjects :: Moderate to severe
medicine.medical_specialty
business.industry
Internal medicine
Ustekinumab
Gastroenterology
Medicine
In patient
General Medicine
business
medicine.disease
Ulcerative colitis
medicine.drug

Tools